2026-04-29T00:59:55Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/181132024-09-27T12:01:37Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Messina, Carlo
author
Cattrini, Carlo
author
Soldato, Davide
author
Vallome, Giacomo
author
Caffo, Orazio
author
Castro, Elena
author
Olmos, David
author
Boccardo, Francesco
author
Zanardi, Elisa
2024-02-12T19:47:13Z
2024-02-12T19:47:13Z
2020-09-07
1687-8450
http://hdl.handle.net/10668/16298
http://hdl.handle.net/20.500.12105/18113
32963528
10.1155/2020/4986365
Journal of oncology
Despite chemotherapy and novel androgen-receptor signalling inhibitors (ARSi) have been approved during the last decades, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with poor clinical outcomes. Several studies found that germline or acquired DNA damage repair (DDR) defects affect a high percentage of mCRPC patients. Among DDR defects, BRCA mutations show relevant clinical implications. BRCA mutations are associated with adverse clinical features in primary tumors and with poor outcomes in patients with mCRPC. In addition, BRCA mutations predict good response to poly-ADP ribose polymerase (PARP) inhibitors, such as olaparib, rucaparib, and niraparib. However, concerns still remain on the role of extensive mutational testing in prostate cancer patients, given the implications for patients and for their progeny. The present comprehensive review attempts to provide an overview of BRCA mutations in prostate cancer, focusing on their prognostic and predictive roles.
eng
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications.
research article